Novo Nordisk A/S (NYSE:NVO) on Saturday presented new phase 3 data supporting the long-term safety and efficacy of investigational hemophilia A treatment denecimig (Mim8).
• Novo Nordisk shares are consolidating. What’s ahead for NVO stock?
The company said the findings further strengthen its hemophilia portfolio as denecimig remains under U.S. Food and Drug Administration (FDA) review following a Biologics License Application submitted in September 2025.
Long-Term Data Reinforces Denecimig’s Safety and Bleeding Control
The interim analysis from the open-label Phase 3 FRONTIER4 extension study included 426 patients aged one year and older with hemophilia A, including individuals with and without inhibitors.
